Azenosertib survival data released by Zentalis Pharmaceuticals on October 18, 2026, showed median overall survival of 15.8 months in patients with Cyclin E1-positive platinum-resistant ovarian cancer. The interim DENALI Part 1b findings appeared in an ESMO Congress abstract ahead of a scheduled October 23 presentation. Azenosertib remains investigational, and the analysis does not establish a survival advantage over chemotherapy.
Key Takeaways
- Median overall survival was 15.8 months in the Cyclin E1-positive subgroup and 7.5 months in the negative subgroup.
- Both subgroups received azenosertib; biomarker status was determined retrospectively.
- Zentalis is pursuing biomarker-selected development through DENALI Part 2 and the randomized ASPENOVA trial.
Table of Contents
- Azenosertib survival data separate two biomarker groups
- What the interim analysis can establish
- Later-stage trials define the approval path
- Conclusion
Azenosertib survival data separate two biomarker groups
The Cyclin E1-positive subgroup included 48 patients, with a 95% confidence interval for median overall survival of 8.7–17.8 months. The negative subgroup included 46 patients, with a corresponding interval of 5.8–12.3 months. Zentalis reported no new safety signals in the interim analysis.
DENALI Part 1b enrolled patients regardless of Cyclin E1 protein expression. Participants had received between one and five prior lines of therapy, including required prior treatment with bevacizumab. Researchers subsequently determined Cyclin E1 status using an immunohistochemistry test and a proprietary cutoff; 94 of the 102 enrolled patients were evaluable for that classification.
The findings underpin Zentalis’ focus on patients whose tumors overexpress Cyclin E1, rather than an unselected ovarian cancer population. The company is developing azenosertib as an oral inhibitor of WEE1, a protein involved in regulating cell division.
| Item | Details |
|---|---|
| Interim data cutoff | September 2, 2025 |
| DENALI Part 1b enrollment | 102 patients with platinum-resistant ovarian cancer |
| Treatment schedule | 400 mg once daily for five days, followed by two days without treatment |
| Primary endpoint | Objective response rate under RECIST v1.1 |
| ESMO presentation | October 23, 2026, in Madrid; rapid oral presentation 1242RO |
What the interim analysis can establish
Overall survival was a secondary endpoint, not the primary measure of the study. The abstract described survival in the Cyclin E1-positive subgroup as favorable against historical single-agent chemotherapy benchmarks, but that is not a direct randomized comparison.
The difference between the two biomarker groups also should not be read as the amount of survival gained from treatment: both groups received azenosertib. The retrospective subgroup analysis supports further testing of the biomarker-led strategy rather than proving superiority over an alternative therapy.
Likewise, the absence of new safety signals does not mean the drug is free of adverse effects. The results remain interim and reflect the specified data cutoff, rather than outcomes through the October 2026 announcement date.
Later-stage trials define the approval path
Zentalis’ August 2026 development update set an expected DENALI Part 2 topline readout in the first half of 2027. That earlier guidance allows for data maturation after full enrollment; it is an expected milestone, not a completed result.
The October announcement said enrollment in DENALI Part 2b was complete, while Part 2c, intended to include approximately 40 patients previously treated with a taxane-containing regimen for platinum-resistant disease, was enrolling. Part 2 is designed to support potential accelerated approval, subject to positive results and further FDA discussions.
The randomized Phase 3 ASPENOVA confirmatory trial is expected to enroll approximately 420 patients with Cyclin E1-positive disease. It compares azenosertib with an investigator-selected single-agent chemotherapy, using progression-free survival as the primary endpoint and overall survival among its key secondary endpoints. That design provides a direct treatment comparison missing from the Part 1b subgroup findings.
Conclusion
The next scheduled event is the October 23, 2026, ESMO rapid oral presentation. The interim survival findings add evidence for Zentalis’ biomarker-selected development strategy, while later-stage results remain necessary to assess comparative benefit and any potential approval.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
